immpact-international

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

Covalent Bruton tyrosine kinase inhibitors (BTKis) and the BCL2 inhibitor venetoclax have significantly improved outcomes for patients with chronic lymphocytic leukemia (CLL), especially those with biologically adverse disease. Patients with CLL resistant to their first targeted agent (TA) can be effectively treated with the alternative class. However, relapses are expected with second-line TA therapy, and…

Read More
immpact-international

Circular RNA SERPINE2 promotes development of glioblastoma by regulating the miR-361-3p/miR-324-5p/ BCL2 signaling pathway

Round RNA (circRNA) is a brand new kind of long-sequence RNA fashioned by a noncanonical type of different splicing referred to as back-splicing. Rising proof has revealed that circRNAs are concerned in most cancers development, regulating cancer-related genes via sponging microRNAs (miRNAs). In our examine, we recognized a novel upregulated circRNA, circSERPINE2, via analyzing circRNAs microarray…

Read More